NASDAQ:AVXL - Anavex Life Sciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.89 -0.06 (-2.03 %)
(As of 04/18/2019 04:00 PM ET)
Previous Close$2.95
Today's Range$2.82 - $2.98
52-Week Range$1.25 - $4.35
Volume205,274 shs
Average Volume454,666 shs
Market Capitalization$137.22 million
P/E RatioN/A
Dividend YieldN/A
Beta2.55
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis. It is also developing ANAVEX 3-71 to treat Alzheimer's disease; ANAVEX 1-41, a sigma-1 agonist; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was founded in 2006 and is based in New York, New York.

Receive AVXL News and Ratings via Email

Sign-up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AVXL
CUSIPN/A
Phone844-689-3939

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.45 per share

Profitability

Net Income$-17,450,000.00

Miscellaneous

Employees13
Market Cap$137.22 million
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable

Anavex Life Sciences (NASDAQ:AVXL) Frequently Asked Questions

What is Anavex Life Sciences' stock symbol?

Anavex Life Sciences trades on the NASDAQ under the ticker symbol "AVXL."

How were Anavex Life Sciences' earnings last quarter?

Anavex Life Sciences Corp (NASDAQ:AVXL) announced its quarterly earnings data on Thursday, February, 7th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.03. View Anavex Life Sciences' Earnings History.

When is Anavex Life Sciences' next earnings date?

Anavex Life Sciences is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Anavex Life Sciences.

What price target have analysts set for AVXL?

4 analysts have issued 12-month price objectives for Anavex Life Sciences' stock. Their forecasts range from $7.00 to $10.00. On average, they expect Anavex Life Sciences' stock price to reach $8.50 in the next year. This suggests a possible upside of 194.1% from the stock's current price. View Analyst Price Targets for Anavex Life Sciences.

What is the consensus analysts' recommendation for Anavex Life Sciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Anavex Life Sciences.

What are Wall Street analysts saying about Anavex Life Sciences stock?

Here are some recent quotes from research analysts about Anavex Life Sciences stock:
  • 1. According to Zacks Investment Research, "ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways. " (4/10/2019)
  • 2. HC Wainwright analysts commented, "We value Anavex on the potential of ANAVEX2-73 in Alzheimer’s disease (AD), Rett syndrome, and Parkinson’s disease dementia (PDD). We use a probability adjusted revenue projection for our therapeutic models. In AD we use just 30%, as the current data set, while encouraging, is small." (10/22/2018)
  • 3. Maxim Group analysts commented, "Anavex reported the June quarter with a net loss of $2.8 million and ended the period with $25.8M in cash, runway into 2H19." (8/9/2018)

Has Anavex Life Sciences been receiving favorable news coverage?

Media coverage about AVXL stock has been trending somewhat negative on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Anavex Life Sciences earned a coverage optimism score of -1.6 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the stock's share price in the near term.

Who are some of Anavex Life Sciences' key competitors?

What other stocks do shareholders of Anavex Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO), POET Technologies (POETF), Sanchez Energy (SN), Brainstorm Cell Therapeutics (BCLI), VASCO Data Security International (VDSI), CytRx (CYTR), Arch Therapeutics (ARTH), Novavax (NVAX), Energous (WATT) and Geron (GERN).

Who are Anavex Life Sciences' key executives?

Anavex Life Sciences' management team includes the folowing people:
  • Dr. Christopher U. Missling, Chairman, Pres, CEO & Sec. (Age 53)
  • Ms. Sandra Boenisch, Principal Financial Officer & Treasurer (Age 38)
  • Mr. Stephan Toutain, Sr. VP of Operations (Age 53)
  • Scott Gordon, Core of Investor Relations
  • Dr. Emmanuel O. Fadiran RPh, Ph.D., Sr. VP of Regulatory Affairs

Who are Anavex Life Sciences' major shareholders?

Anavex Life Sciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Tibra Equities Europe Ltd (0.18%), Virtu Financial LLC (0.10%), Edge Wealth Management LLC (0.06%) and Wedbush Securities Inc. (0.03%). View Institutional Ownership Trends for Anavex Life Sciences.

Which institutional investors are buying Anavex Life Sciences stock?

AVXL stock was purchased by a variety of institutional investors in the last quarter, including Tibra Equities Europe Ltd, Virtu Financial LLC, Edge Wealth Management LLC and Wedbush Securities Inc.. View Insider Buying and Selling for Anavex Life Sciences.

How do I buy shares of Anavex Life Sciences?

Shares of AVXL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anavex Life Sciences' stock price today?

One share of AVXL stock can currently be purchased for approximately $2.89.

How big of a company is Anavex Life Sciences?

Anavex Life Sciences has a market capitalization of $137.22 million. The biotechnology company earns $-17,450,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Anavex Life Sciences employs 13 workers across the globe.

What is Anavex Life Sciences' official website?

The official website for Anavex Life Sciences is http://www.anavex.com.

How can I contact Anavex Life Sciences?

Anavex Life Sciences' mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 844-689-3939 or via email at [email protected]


MarketBeat Community Rating for Anavex Life Sciences (NASDAQ AVXL)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  288 (Vote Outperform)
Underperform Votes:  158 (Vote Underperform)
Total Votes:  446
MarketBeat's community ratings are surveys of what our community members think about Anavex Life Sciences and other stocks. Vote "Outperform" if you believe AVXL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVXL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel